Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rahul Aggarwal

Showing results (211-220 of 223) with videos related to

Pageof 23
Sort By:
NPJ Precision Oncology|July 7, 2025
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancerAnbarasu Kumaraswamy, Ya-Mei Hu, Joel A Yates, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 20, 2020
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistanceJoshi J Alumkal, Duanchen Sun, Eric Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2020
Autoantibody Landscape in Patients with Advanced Prostate CancerWilliam S Chen, Winston A Haynes, Rebecca Waitz, et al.
Prostate Cancer and Prostatic Diseases|February 27, 2019
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancerNicholas G Nickols, Ramin Nazarian, Shuang G Zhao, et al.
Nature Communications|December 22, 2021
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancerNeha Singh, Varune R Ramnarine, Jin H Song, et al.
European Urology Oncology|December 10, 2023
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate CancerJacob J Orme, Fadi Taza, Navonil De Sarkar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2021
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity ProgramDae-Hwan Kim, Duanchen Sun, William K Storck, et al.
Nature Communications|September 15, 2022
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticityThomas C Westbrook, Xiangnan Guan, Eva Rodansky, et al.
The Journal of Clinical Investigation|June 2, 2025
PROX1 is an early driver of lineage plasticity in prostate cancerZhi Duan, Mingchen Shi, Anbarasu Kumaraswamy, et al.
Cell|July 24, 2018
Genomic Hallmarks and Structural Variation in Metastatic Prostate CancerDavid A Quigley, Ha X Dang, Shuang G Zhao, et al.
Pageof 23

Showing results (211-220 of 223) with videos related to

Sort By:
Pageof 23
NPJ Precision Oncology|July 7, 2025
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancerAnbarasu Kumaraswamy, Ya-Mei Hu, Joel A Yates, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 20, 2020
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistanceJoshi J Alumkal, Duanchen Sun, Eric Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2020
Autoantibody Landscape in Patients with Advanced Prostate CancerWilliam S Chen, Winston A Haynes, Rebecca Waitz, et al.
Prostate Cancer and Prostatic Diseases|February 27, 2019
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancerNicholas G Nickols, Ramin Nazarian, Shuang G Zhao, et al.
Nature Communications|December 22, 2021
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancerNeha Singh, Varune R Ramnarine, Jin H Song, et al.
European Urology Oncology|December 10, 2023
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate CancerJacob J Orme, Fadi Taza, Navonil De Sarkar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2021
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity ProgramDae-Hwan Kim, Duanchen Sun, William K Storck, et al.
Nature Communications|September 15, 2022
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticityThomas C Westbrook, Xiangnan Guan, Eva Rodansky, et al.
The Journal of Clinical Investigation|June 2, 2025
PROX1 is an early driver of lineage plasticity in prostate cancerZhi Duan, Mingchen Shi, Anbarasu Kumaraswamy, et al.
Cell|July 24, 2018
Genomic Hallmarks and Structural Variation in Metastatic Prostate CancerDavid A Quigley, Ha X Dang, Shuang G Zhao, et al.
Pageof 23